MiR-92a, a small non-coding RNA, is a newly discovered biomarker with high sensitivity and specificity to CRC. REColonTM miR-92a Assay Kit, the 1st CFDA approved stool-based colorectal cancer diagnostic kit, works through detecting miR-92a level directly from CRC cells shed from lining of human colon and eventually excreted in the stool. By co-working with existing clinical tests, REColonTM serves as an effective tool for CRC screening, early diagnosis and postoperative monitoring.